Ethic Inc. acquired a new position in HCA Healthcare, Inc. (NYSE:HCA) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,920 shares of the company’s stock, valued at approximately $239,000.
A number of other institutional investors have also recently bought and sold shares of the stock. JustInvest LLC purchased a new stake in HCA Healthcare in the 3rd quarter worth about $247,000. Empowered Funds LLC purchased a new stake in HCA Healthcare in the 3rd quarter worth about $2,642,000. Clear Harbor Asset Management LLC grew its stake in HCA Healthcare by 11.3% in the 3rd quarter. Clear Harbor Asset Management LLC now owns 6,405 shares of the company’s stock worth $799,000 after acquiring an additional 650 shares in the last quarter. 180 Wealth Advisors LLC bought a new position in HCA Healthcare in the 3rd quarter worth about $236,000. Finally, Cryder Capital Partners LLP grew its stake in HCA Healthcare by 17.9% in the 3rd quarter. Cryder Capital Partners LLP now owns 952,090 shares of the company’s stock worth $118,707,000 after acquiring an additional 144,607 shares in the last quarter. 68.28% of the stock is currently owned by institutional investors.
Shares of HCA opened at $125.40 on Friday. The company has a market cap of $42.39 billion, a price-to-earnings ratio of 12.93, a price-to-earnings-growth ratio of 1.20 and a beta of 1.39. HCA Healthcare, Inc. has a twelve month low of $58.38 and a twelve month high of $151.97. The company has a quick ratio of 0.95, a current ratio of 1.09 and a debt-to-equity ratio of 54.19. The company has a 50 day moving average of $130.67 and a two-hundred day moving average of $117.46.
HCA Healthcare (NYSE:HCA) last announced its earnings results on Monday, October 26th. The company reported $1.92 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $2.69 by ($0.77). The firm had revenue of $13.31 billion during the quarter, compared to analyst estimates of $12.92 billion. HCA Healthcare had a net margin of 6.67% and a negative return on equity of 589.47%. HCA Healthcare’s revenue was up 4.9% on a year-over-year basis. During the same quarter last year, the business earned $2.23 earnings per share. On average, sell-side analysts expect that HCA Healthcare, Inc. will post 10.12 EPS for the current year.
The business also recently declared a monthly dividend, which will be paid on Thursday, November 12th. Shareholders of record on Friday, October 30th will be issued a $0.072 dividend. The ex-dividend date of this dividend is Thursday, October 29th. This represents a $0.86 dividend on an annualized basis and a dividend yield of 0.69%.
In related news, insider A Bruce Moore, Jr. sold 15,000 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $133.73, for a total transaction of $2,005,950.00. Following the completion of the transaction, the insider now owns 88,626 shares of the company’s stock, valued at $11,851,954.98. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP P. Martin Paslick sold 850 shares of the firm’s stock in a transaction on Tuesday, October 27th. The stock was sold at an average price of $133.50, for a total transaction of $113,475.00. Following the transaction, the senior vice president now directly owns 1,771 shares of the company’s stock, valued at approximately $236,428.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,331 shares of company stock valued at $2,183,838. Corporate insiders own 1.80% of the company’s stock.
A number of brokerages have commented on HCA. Piper Sandler upped their target price on shares of HCA Healthcare from $138.00 to $149.00 and gave the stock a “neutral” rating in a research note on Tuesday. Mizuho upped their target price on shares of HCA Healthcare from $145.00 to $150.00 and gave the stock a “buy” rating in a research note on Tuesday. Barclays upped their target price on shares of HCA Healthcare from $140.00 to $150.00 and gave the stock an “overweight” rating in a research note on Tuesday. Raymond James increased their price objective on shares of HCA Healthcare from $140.00 to $150.00 and gave the company an “outperform” rating in a research note on Tuesday. Finally, ValuEngine upgraded shares of HCA Healthcare from a “sell” rating to a “hold” rating in a research note on Tuesday. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $152.10.
HCA Healthcare Company Profile
HCA Healthcare, Inc, through its subsidiaries, operates as a health care services company in the United States. The company operates general, acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy services.
Further Reading: What is the Fibonacci sequence?
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.